Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA, Financial Terms Undisclosed
Portfolio Pulse from Benzinga Newsdesk
Genezen is set to acquire uniQure's commercial gene therapy manufacturing operations in Lexington, MA. The acquisition includes a strategic supply agreement for uniQure's clinical portfolio and CSL's HEMGENIX® product. The Lexington site will serve as Genezen's global AAV center of excellence.
July 01, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
uniQure is selling its commercial gene therapy manufacturing operations in Lexington, MA to Genezen. This includes strategic supply agreements for uniQure's clinical portfolio and CSL's HEMGENIX® product.
The sale of the Lexington facility and the strategic supply agreements could provide uniQure with additional resources and focus on its clinical portfolio, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100